The Double-Edged Sword of Unprofitable Stocks: Navigating the Risky Terrain of DURECT’s Cash Burn
Biotech startups like DURECT Corporation face the dual challenges of innovation and financial vulnerability, balancing vision with stability. DURECT ended 2024 with only $12 million in cash, struggling against a…